Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis patients, from a Phase 3 study

Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis patients, from a Phase 3 study

Bibliografske podrobnosti
Main Authors:	Emery, P, Taylor, P, Weinblatt, M, Tanaka, Y, Keystone, E, Dow, E, Higgs, R, Macias, W, Rocha, G, Rooney, T, Schlichting, D, Zuckerman, S, McInnes, I
Format:	Conference item
Jezik:	English
Izdano:	Wiley 2017

Podobne knjige/članki

Baricitinib versus placebo or adalimumab in rheumatoid arthritis
od: Taylor, P, et al.
Izdano: (2017)

Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis
od: Tanaka, Y, et al.
Izdano: (2018)

Efficacy and safety of switching from adalimumab to baricitinib: Phase 3 data in patients with rheumatoid arthritis
od: Taylor, P, et al.
Izdano: (2016)

Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis
od: Taylor, P, et al.
Izdano: (2017)

Efficacy and safety of switching from adalimumab to baricitinib: long-term data from phase 3 extension study in patients with rheumatoid arthritis
od: Weinblatt, M, et al.
Izdano: (2018)

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
od: Keystone, E, et al.
Izdano: (2017)

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
od: Tanaka, Y, et al.
Izdano: (2019)

Rapid and sustained pain improvement in rheumatoid arthritis patients treated with baricitinib compared to adalimumab or placebo
od: Taylor, P, et al.
Izdano: (2017)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
od: Weinblatt, M, et al.
Izdano: (2017)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
od: Keystone, E, et al.
Izdano: (2015)

Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase 2b study in patients with active rheumatoid arthritis
od: Kremer, J, et al.
Izdano: (2017)

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
od: Paul Emery, et al.
Izdano: (2020-05-01)

Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
od: Paul Emery, et al.
Izdano: (2020-07-01)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
od: Taylor, P, et al.
Izdano: (2019)

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
od: Schlueter M, et al.
Izdano: (2019-06-01)

Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis
od: Keystone, EC, et al.
Izdano: (2017)

Patient disease trajectories in baricitinib-treated patients with rheumatoid arthritis and inadequate response to methotrexate
od: Taylor, P, et al.
Izdano: (2019)

Cardiovascular safety - Update from up to 6 years of treatment with baricitinib in rheumatoid arthritis clinical trials
od: Weinblatt, M, et al.
Izdano: (2018)

Use of magnetic resonance imaging to support dose selection in a phase II trial of baricitinib combined with conventional synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis
od: Peterfy, C, et al.
Izdano: (2019)

Improved patient-reported outcomes in patients with rheumatoid arthritis who failed adalimumab or placebo treatment and were rescued with baricitinib
od: Fautrel, B, et al.
Izdano: (2017)

Baricitinib for the treatment of rheumatoid arthritis
od: Ivan Urits, et al.
Izdano: (2020-12-01)

Baricitinib contre placebo ou adalimumab chez des patients atteints de polyarthrite rhumatoïde (PR) active et présentant une réponse inadéquate au méthotrexate (MTX) : Résultats d’une étude de phase 3 de 52 semaines RA-BEAM
od: Taylor, P, et al.
Izdano: (2016)

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies
od: Taylor, PC, et al.
Izdano: (2018)

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience
od: Taylor, PC, et al.
Izdano: (2023)

24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
od: Taylor, P, et al.
Izdano: (2013)

Baricitinib provides greater improvements in patient-reported outcomes across all disease activity levels compared to placebo and adalimumab in rheumatoid arthritis
od: Taylor, P, et al.
Izdano: (2021)

Baricitinib exposure during pregnancy in rheumatoid arthritis
od: Giulia Costanzo, et al.
Izdano: (2020-01-01)

Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.
od: Peterfy, C, et al.
Izdano: (2012)

Baricitinib: Early vs. delayed start in patients with rheumatoid arthritis
od: Taylor, P, et al.
Izdano: (2018)

Cost per number needed to treat and treatment cost of baricitinib versus adalimumab on rheumatoid arthritis treatment in the brazilian private healthcare system
od: Bruno Corona Prandi, et al.
Izdano: (2023-02-01)

Achieving pain control in rheumatoid arthritis with baricitinib or ddalimumab plus methotrexate: Results from the RA-BEAM Trial
od: Taylor, P, et al.
Izdano: (2019)

Efficacy and safety of baricitinib versus placebo and adalimumab in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate: Summary results from the 52-week phase 3 RA-beam study
od: Taylor, P, et al.
Izdano: (2017)

Patient disease trajectories in rheumatoid arthritis patients treated with baricitinib 4-mg in 4 phase 3 clinical studies
od: Taylor, PC, et al.
Izdano: (2023)

Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM
od: Fautrel, B, et al.
Izdano: (2019)

Problems of pain and quality of life in rheumatoid arthritis: focus on baricitinib
od: A. E. Karateev
Izdano: (2020-09-01)

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
od: Smolen, JS, et al.
Izdano: (2024)

Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations
od: Iain B. McInnes, et al.
Izdano: (2019-08-01)

24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.
od: Genovese, M, et al.
Izdano: (2012)

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
od: Kawalec P, et al.
Izdano: (2019-02-01)

Lack of clinical disease activity response at 4 weeks of baricitinib treatment as a negative predictor of remission at weeks 12 and 24 in patients with rheumatoid arthritis: results from two phase 3 studies (RA-BEAM and RA-BEGIN)
od: Tanaka, Y, et al.
Izdano: (2021)